Anti-Inflammatory Tripeptide | Alpha-MSH Fragment
DoseGear research brief
KPV is a potent anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It exhibits remarkable anti-inflammatory and antimicrobial properties without the pigmentation effects of full α-MSH, making it ideal for inflammation management.
Enters cells and inhibits inflammatory pathways at the nuclear level, particularly NF-κB signaling. Reduces pro-inflammatory cytokines (TNF-α, IL-6) without causing immunosuppression like steroids.
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
Lys–Pro–Val tripeptide corresponding to the C-terminal region of alpha-MSH.
Experimental inflammatory and epithelial-barrier research with proposed NF-κB-related anti-inflammatory signaling.
Not reported in the reviewed compound-specific evidence.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| General anti-inflammatory | 200-300mcg | Once daily | SubQ |
| Active inflammation | 250mcg | Twice daily | SubQ |
| Autoimmune support | 500mcg | Once daily | SubQ |
| Acute flare-ups | 500mcg | 2x daily for 1 week, then reduce | SubQ |
Reference cycle
4-8 weeks
Reference storage
Lyophilized: Room temperature; Reconstituted: 2-8°C, refrigerate immediately
Dissection of the Anti-Inflammatory Effect of the Core and C-Terminal (KPV) Alpha-Melanocyte-Stimulating Hormone Peptides
PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation
Melanocortin-Derived Tripeptide KPV Has Anti-Inflammatory Potential in Murine Models of Inflammatory Bowel Disease
Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of KPV
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.
